Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Total Enrollment

25 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to document the pharmacological treatment strategies used in treatment naïve and previously treated relapsed/refractory iNHL/CLL patients in the Middle East and North African (MENA) region. This study will also record encountered tumor subtype and stage and the instituted pharmacological treatments, as well as assess the clinical outcomes of treatments.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

NCT02561273

Anaplastic Large Cell Lymphoma, ALK-Negative Anaplastic Large Cell Lymphoma, ALK-Positive Hepatosplenic T-Cell Lymphoma +7 more

COMPLETED PHASE1/PHASE2

A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

NCT05205161

Non-Hodgkin Lymphoma

TERMINATED PHASE1

Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma

NCT00005803

Prolymphocytic Leukemia Recurrent Adult Hodgkin Lymphoma Recurrent Childhood Hodgkin Lymphoma +11 more

COMPLETED PHASE1/PHASE2

Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas

NCT00704691

Peripheral T-cell Lymphomas Adult T-cell Leukemia Adult T-cell Lymphoma +5 more

TERMINATED EARLY_PHASE1

Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia

NCT00005977

Leukemia Lymphoma

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be followed up to 30 months.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Indolent Non Hodgkin's Lymphoma (iNHL) Chronic Lymphocytic Leukaemia (CLL)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment naïve patients with CLL

No interventions assigned to this group

Treatment naïve patients with iNHL

No interventions assigned to this group

Relapsed/refractory patients with CLL

No interventions assigned to this group

Relapsed/refractory patients with iNHL

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent
* CLL patients or
* iNHL patients
* Clinical decision made to initiate or adapt treatment of CLL/iNHL("Need to treat")

Exclusion Criteria

* Patient deemed unfit for enrollment by the documented opinion of the investigator
* Watch and wait patients
* Richter's transformation
* Patients otherwise not eligible for (pharmacological) intervention
* Moribund patients

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No